Whitehawk Therapeutics Inc

NASDAQ:WHWK

Biotechnology

Healthcare
$3.13 +1.42%

+$0.06 today

Market cap
$184.70M
Beta
0.77
P/E (TTM)
-2.6
EPS (TTM)
-$1.67
52W Low $1.57High $5.50

Volume 0.28M

Average 0.31M

WHWK Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Whitehawk Therapeutics IncNASDAQ: WHWK

Other Non-Cash Items · Q4 FY2025 · quarter ended Dec 2025

Other non-cash items grows, but more slowly than its trailing trend

Q4 FY2025 other non-cash items of $1.56M rose 220.6% year over year, behind the +713.4% change in trailing-twelve-month other non-cash items.

Context

  • Other non-cash items amounted to 1102.4% of revenue in FY2025, up 1061.6 pp from a year earlier.
  • Other non-cash items increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +220.6% toward the trailing-twelve-month pace of +713.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$1.56M+388.5% QoQ
Last fiscal yearDec 2025
-$78.77M+642.1% YoY
LTMDec 2025
-$86.33M+713.4% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+220.6%——
1 year+642.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
(78.77M) USD
Year-over-year change
-642.1%

Other Non-Cash Items vs competitors

How WHWK compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +713.4% is the 2nd highest of 9, against a peer median of -32.5%.
  • Other non-cash items amounts to 1208.3% of revenue for WHWK, versus a peer median of 279.4%.
WHWK Competitors
Other Non-Cash Items for WHWK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WHWKWhitehawk Therapeutics IncLTM Dec 2025$86.33M USD+713.4%—1208.3%
OVIDOvid Therapeutics Inc.LTM Mar 2026$19.9M USD-29.1%+205.9%279.4%
PLRXPliant Therapeutics, Inc.LTM Mar 2026$14.42M USD+126.6%+457.6%—
CLNNClene Inc.LTM Mar 2026$12.53M USD+5079.4%—9353.8%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$4.88M CAD+407.6%——
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$4.69M USD-173.0%——
CNTXContext Therapeutics Inc.LTM Mar 2026$2.11M USD-85.7%+53.9%—
MGNXMacroGenics, Inc.LTM Mar 2026$1.21M USD-96.9%-31.8%0.8%
IMMXImmix Biopharma, Inc.LTM Mar 2026$1.03M USD-35.9%——
Peer median (excluding WHWK) —-32.5%+129.9%279.4%

Competitors are the stored peer set for WHWK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(110.09M)(60.51M)(65.77M)(63.69M)(20.6M)
Depreciation & Amortization105K159K169K193K79K
Deferred Income Tax00000
Stock-Based Compensation2.11M9.64M11.95M10.84M9.87M
Change in Working Capital3.96M(5.04M)(3.27M)3.72M1.93M
Accounts Receivables14.15M(1.86M)(3.63M)(415K)(1M)
Inventory0(1.86M)(3.27M)1.12M170K
Accounts Payables00003.92M
Other Working Capital(10.19M)(1.32M)3.62M3.02M(1.16M)
Other Non-Cash Items81.5M6.11M(2.75M)(10.61M)(78.77M)
Operating Cash Flow(22.42M)(49.64M)(59.66M)(59.55M)(97.43M)
Capital Expenditures(46K)(444K)(3.97M)(1.65M)(552K)
Acquisitions (Net)25.2M000101.29M
Purchases of Investments0(145.19M)(64.44M)(36.48M)(148.69M)
Sales of Investments012.75M151.62M63.34M59.85M
Other Investing Activities00000
Investing Cash Flow25.15M(132.89M)83.21M25.2M11.89M
Debt Repayment00000
Common Stock Issued155M72.5M0130K100M
Common Stock Repurchased00000
Dividends Paid(4.41M)0000
Other Financing Activities(8.78M)120K326K(16K)(5.63M)
Financing Cash Flow141.8M72.62M326K130K94.38M
Effect of Forex Changes000064K
Net Change in Cash144.53M(109.91M)23.87M(34.22M)8.9M
Free Cash Flow(22.47M)(50.08M)(63.64M)(61.2M)(97.99M)

Whitehawk Therapeutics Inc

NASDAQ:WHWK

Intrinsic Alpha fair value

Locked

Current Price

$3.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.